Global Sunitinib Malate Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Sunitinib Malate Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Sunitinib Malate is the orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation. This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.
Global Sunitinib Malate market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Advanced Kidney Cancer and GIST (Gastrointestinal Stromal Tumor) are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Sunitinib Malate industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Sunitinib Malate key manufacturers include Pfizer Sutent, Topcare pharmaceutical Co., Ltd, Nanjing First Pharmaceutical Co., Ltd., J&K Scientific, Target Molecule Corp., CSPC, Qilu Pharmaceutical and Hansoh Pharma, etc. Pfizer Sutent, Topcare pharmaceutical Co., Ltd, Nanjing First Pharmaceutical Co., Ltd. are top 3 players and held % sales share in total in 2022.
Sunitinib Malate can be divided into 12.5mg, 37.5mg and 50mg,, etc. 12.5mg is the mainstream product in the market, accounting for % sales share globally in 2022.
Sunitinib Malate is widely used in various fields, such as Advanced Kidney Cancer, GIST (Gastrointestinal Stromal Tumor) and Pancreatic Neuroendocrine Tumors,, etc. Advanced Kidney Cancer provides greatest supports to the Sunitinib Malate industry development. In 2022, global % sales of Sunitinib Malate went into Advanced Kidney Cancer filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sunitinib Malate market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Pfizer Sutent
Topcare pharmaceutical Co., Ltd
Nanjing First Pharmaceutical Co., Ltd.
J&K Scientific
Target Molecule Corp.
CSPC
Qilu Pharmaceutical
Hansoh Pharma
Segment by Type
12.5mg
37.5mg
50mg
Advanced Kidney Cancer
GIST (Gastrointestinal Stromal Tumor)
Pancreatic Neuroendocrine Tumors
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Sunitinib Malate market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Sunitinib Malate, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Sunitinib Malate industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Sunitinib Malate in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Sunitinib Malate introduction, etc. Sunitinib Malate Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Sunitinib Malate market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Global Sunitinib Malate market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Advanced Kidney Cancer and GIST (Gastrointestinal Stromal Tumor) are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Sunitinib Malate industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Sunitinib Malate key manufacturers include Pfizer Sutent, Topcare pharmaceutical Co., Ltd, Nanjing First Pharmaceutical Co., Ltd., J&K Scientific, Target Molecule Corp., CSPC, Qilu Pharmaceutical and Hansoh Pharma, etc. Pfizer Sutent, Topcare pharmaceutical Co., Ltd, Nanjing First Pharmaceutical Co., Ltd. are top 3 players and held % sales share in total in 2022.
Sunitinib Malate can be divided into 12.5mg, 37.5mg and 50mg,, etc. 12.5mg is the mainstream product in the market, accounting for % sales share globally in 2022.
Sunitinib Malate is widely used in various fields, such as Advanced Kidney Cancer, GIST (Gastrointestinal Stromal Tumor) and Pancreatic Neuroendocrine Tumors,, etc. Advanced Kidney Cancer provides greatest supports to the Sunitinib Malate industry development. In 2022, global % sales of Sunitinib Malate went into Advanced Kidney Cancer filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sunitinib Malate market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Pfizer Sutent
Topcare pharmaceutical Co., Ltd
Nanjing First Pharmaceutical Co., Ltd.
J&K Scientific
Target Molecule Corp.
CSPC
Qilu Pharmaceutical
Hansoh Pharma
Segment by Type
12.5mg
37.5mg
50mg
Segment by Application
Advanced Kidney Cancer
GIST (Gastrointestinal Stromal Tumor)
Pancreatic Neuroendocrine Tumors
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Sunitinib Malate market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Sunitinib Malate, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Sunitinib Malate industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Sunitinib Malate in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Sunitinib Malate introduction, etc. Sunitinib Malate Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Sunitinib Malate market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices